Cardiol Therapeutics Net Worth
Cardiol Therapeutics Net Worth Breakdown | CRDL |
Cardiol Therapeutics Net Worth Analysis
Cardiol Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Cardiol Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Cardiol Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Cardiol Therapeutics' net worth analysis. One common approach is to calculate Cardiol Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Cardiol Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Cardiol Therapeutics' net worth. This approach calculates the present value of Cardiol Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Cardiol Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Cardiol Therapeutics' net worth. This involves comparing Cardiol Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Cardiol Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Cardiol Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cardiol Therapeutics' net worth research are outlined below:
| Cardiol Therapeutics may become a speculative penny stock | |
| Cardiol Therapeutics had very high historical volatility over the last 90 days | |
| Cardiol Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (28.13 K) with profit before overhead, payroll, taxes, and interest of 78.76 K. | |
| Cardiol Therapeutics Class currently holds about 70.45 M in cash with (25.18 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.14. | |
| Cardiol Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Cardiol Therapeutics Inc. Short Interest Update |
Cardiol Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cardiol Therapeutics Class. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cardiol Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Cardiol Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cardiol Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cardiol Therapeutics Class backward and forwards among themselves. Cardiol Therapeutics' institutional investor refers to the entity that pools money to purchase Cardiol Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 52.4 K | Bank Of Montreal | 2024-12-31 | 50 K | Bmo Capital Markets Corp. | 2024-12-31 | 50 K | Virtu Financial Llc | 2024-12-31 | 48 K | Cetera Investment Advisers | 2024-12-31 | 43.5 K | Citadel Advisors Llc | 2024-12-31 | 38.1 K | Marble Harbor Investment Counsel, Llc | 2024-12-31 | 36.9 K | Goldman Sachs Group Inc | 2024-12-31 | 35.9 K | Royal Bank Of Canada | 2024-12-31 | 24.8 K | Tejara Capital Ltd | 2024-12-31 | 3.1 M | Advisorshares Investments, Llc | 2024-12-31 | 882.5 K |
Follow Cardiol Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 97.57 M.Market Cap |
|
Project Cardiol Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.69) | (0.73) | |
| Return On Capital Employed | (1.21) | (1.27) | |
| Return On Assets | (0.69) | (0.72) | |
| Return On Equity | (0.90) | (0.94) |
When accessing Cardiol Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Cardiol Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cardiol Therapeutics' profitability and make more informed investment decisions.
Evaluate Cardiol Therapeutics' management efficiency
Cardiol Therapeutics has return on total asset (ROA) of (0.7907) % which means that it has lost $0.7907 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5953) %, meaning that it created substantial loss on money invested by shareholders. Cardiol Therapeutics' management efficiency ratios could be used to measure how well Cardiol Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.73. The value of Return On Capital Employed is expected to slide to -1.27. At this time, Cardiol Therapeutics' Non Current Assets Total are quite stable compared to the past year. Intangible Assets is expected to rise to about 371 K this year, although the value of Net Tangible Assets will most likely fall to about 32.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.39 | 0.64 | |
| Tangible Book Value Per Share | 0.39 | 0.63 | |
| Enterprise Value Over EBITDA | (1.17) | (1.22) | |
| Price Book Value Ratio | 2.89 | 2.74 | |
| Enterprise Value Multiple | (1.17) | (1.22) | |
| Price Fair Value | 2.89 | 2.74 | |
| Enterprise Value | -18.7 M | -17.8 M |
Management at Cardiol Therapeutics focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Cardiol Therapeutics time-series forecasting models is one of many Cardiol Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cardiol Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Cardiol Therapeutics Earnings per Share Projection vs Actual
Cardiol Therapeutics Corporate Management
| Andrew MD | Chief Development | Profile | |
| Trevor Burns | Investor Relations | Profile | |
| Bernard BSc | Chief Officer | Profile | |
| MBA BSCPT | Vice Development | Profile | |
| MBA MBA | CEO Pres | Profile | |
| CA CMA | Corp CFO | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.